Kymera Therapeutics (NASDAQ:KYMR) Stock Price Down 4.3% - Time to Sell?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) traded down 4.3% during mid-day trading on Tuesday . The stock traded as low as $28.29 and last traded at $28.23. 292,559 shares traded hands during mid-day trading, a decline of 48% from the average session volume of 561,291 shares. The stock had previously closed at $29.49.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Wall Street Zen raised Kymera Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Stifel Nicolaus assumed coverage on Kymera Therapeutics in a report on Tuesday, May 20th. They issued a "buy" rating and a $55.00 target price for the company. HC Wainwright upped their target price on Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a report on Friday, February 28th. Bank of America reduced their price objective on Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating for the company in a report on Monday, May 12th. Finally, Citigroup assumed coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective for the company. Five analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Kymera Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $55.25.

Kymera Therapeutics Stock Down 2.6%

The company has a market capitalization of $1.92 billion, a PE ratio of -12.59 and a beta of 2.18. The company has a 50-day moving average price of $28.58 and a two-hundred day moving average price of $35.66.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last posted its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The company had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm's quarterly revenue was up 114.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.69) earnings per share. As a group, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Insider Activity at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the completion of the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. The trade was a 2.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of Kymera Therapeutics stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now directly owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This trade represents a 3.37% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,659 shares of company stock valued at $324,567. Company insiders own 16.01% of the company's stock.

Institutional Investors Weigh In On Kymera Therapeutics

Several hedge funds have recently added to or reduced their stakes in KYMR. Wellington Management Group LLP lifted its stake in Kymera Therapeutics by 13.0% during the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after purchasing an additional 689,547 shares during the last quarter. Avoro Capital Advisors LLC increased its holdings in Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock valued at $207,184,000 after purchasing an additional 650,000 shares during the period. Deerfield Management Company L.P. Series C purchased a new position in Kymera Therapeutics during the 4th quarter valued at about $23,856,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Kymera Therapeutics by 121.5% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock worth $24,535,000 after acquiring an additional 491,737 shares during the period. Finally, Boxer Capital Management LLC purchased a new position in shares of Kymera Therapeutics during the 4th quarter worth approximately $17,098,000.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.